Becker muscular dystrophy (BMD) is an X-linked recessive muscular dystrophy caused by mutations in the DMD gene that result in partially functional dystrophin protein. It is named after German neurologist Dr. Peter Becker, who first described the condition in 1957. BMD represents the milder end of the phenotypic spectrum of DMD gene disorders, with an estimated prevalence of 1 in 18,500 to 1 in 30,000 male births. [@cardiac]
Unlike Duchenne muscular dystrophy (DMD), which results in virtually no functional dystrophin, BMD is characterized by reduced but partially functional dystrophin protein (typically 10-30% of normal levels). This leads to a milder, more slowly progressive disease course, with many patients surviving into adulthood and some living into their 60s or beyond. [@machine]
Introduction
Becker muscular dystrophy provides a unique window into the biology of dystrophin and its critical role in muscle integrity. The discovery of the DMD gene in 1986 and subsequent understanding of the genotype-phenotype correlation revolutionized both diagnosis and therapeutic development for all muscular dystrophies. [@effects]
The disease demonstrates significant clinical variability, ranging from asymptomatic elevation of creatine kinase to severe progressive weakness with early cardiac involvement. This variability stems directly from the nature of the underlying DMD gene mutation and its effect on the reading frame and protein production. [@screening]
Genetics
DMD Gene
...
Becker Muscular Dystrophy
Overview
Becker muscular dystrophy (BMD) is an X-linked recessive muscular dystrophy caused by mutations in the DMD gene that result in partially functional dystrophin protein. It is named after German neurologist Dr. Peter Becker, who first described the condition in 1957. BMD represents the milder end of the phenotypic spectrum of DMD gene disorders, with an estimated prevalence of 1 in 18,500 to 1 in 30,000 male births. [@cardiac]
Unlike Duchenne muscular dystrophy (DMD), which results in virtually no functional dystrophin, BMD is characterized by reduced but partially functional dystrophin protein (typically 10-30% of normal levels). This leads to a milder, more slowly progressive disease course, with many patients surviving into adulthood and some living into their 60s or beyond. [@machine]
Introduction
Becker muscular dystrophy provides a unique window into the biology of dystrophin and its critical role in muscle integrity. The discovery of the DMD gene in 1986 and subsequent understanding of the genotype-phenotype correlation revolutionized both diagnosis and therapeutic development for all muscular dystrophies. [@effects]
The disease demonstrates significant clinical variability, ranging from asymptomatic elevation of creatine kinase to severe progressive weakness with early cardiac involvement. This variability stems directly from the nature of the underlying DMD gene mutation and its effect on the reading frame and protein production. [@screening]
Genetics
DMD Gene
The DMD gene is located on the short arm of the X chromosome (Xp21.2) and is one of the largest human genes, spanning approximately 2.2 million base pairs. It encodes dystrophin, a critical cytoskeletal protein. [@twoyear]
Types of Mutations in BMD
In-frame deletions: Removal of one or more exons that maintain the reading frame, allowing production of a truncated but partially functional protein. These account for approximately 65-70% of BMD cases.
In-frame duplications: Additional copies of exons that also preserve the reading frame.
Missense mutations: Amino acid substitutions that partially impair dystrophin function without abolishing it.
Nonsense mutations (rare in BMD): Stop codons that allow some read-through, producing limited amounts of functional protein.
Genotype-Phenotype Correlation
The reading frame rule explains most of the difference between DMD and BMD: [^6]
Frameshift mutations → no functional dystrophin → DMD
In-frame mutations → truncated but functional dystrophin → BMD
However, exceptions exist due to: [^7]
Alternative splicing
Promoter usage
Protein stability differences
Inheritance Pattern
BMD follows X-linked recessive inheritance: [^8]
Affected males inherit the mutated gene from their mothers
Female carriers have a 50% chance of passing the mutation to each child
Approximately 30% of cases arise from de novo mutations
Female carriers may show mild symptoms (cardiomyopathy, mild weakness)
Pathophysiology
Dystrophin Function
Dystrophin is a 427 kDa protein that forms a critical link between the actin cytoskeleton and the extracellular matrix through the dystrophin-associated glycoprotein complex (DGC). It functions as:
A shock absorber during muscle contraction
A stabilizer of the sarcolemma
A scaffold for signaling molecules
A regulator of nitric oxide signaling
Defect in BMD
In BMD, the mutations result in:
Reduced dystrophin levels: Typically 10-30% of normal
Truncated protein: Often missing internal segments
Partially preserved function: Can still provide some membrane protection
Downstream Consequences
Despite milder primary defect, BMD muscle still shows:
Sarcolemmal instability during contraction
Increased susceptibility to mechanical damage
Chronic inflammation
Fibrosis accumulation
Metabolic alterations
Cardiac muscle involvement
Cardiac Involvement
Cardiac disease is a hallmark of BMD:
Dilated cardiomyopathy: Develops in 50-70% of patients
Arrhythmias: Including atrial and ventricular ectopy
Heart failure: Typically develops in the third to fourth decade
Conduction abnormalities: May require pacemaker implantation
The myocardium may be affected even in patients with mild skeletal muscle symptoms, making cardiac monitoring essential.
Clinical Features
Age of Onset
Typical onset: Adolescence to early adulthood (5-15 years)
Range: Can present anywhere from early childhood to age 40
Detection: Often incidentally discovered through elevated CK
Muscle Weakness Pattern
Proximal muscles affected first: hips, shoulders
Scapular winging: Due to shoulder girdle weakness
Gower's sign: Using hands to climb up legs when rising from the floor
Waddling gait: Due to hip girdle weakness
Face muscles: Typically spared
Distal muscles: Usually preserved until late disease
Disease Progression
BMD progression is highly variable:
Mild cases: May remain ambulatory into middle age
Moderate cases: Lose ambulation in the fourth to fifth decade
Severe cases: Similar to DMD but less common
Cardiac progression: Often independent of skeletal muscle severity
Other Features
Muscle cramps: Common, especially after exercise
Myoglobinuria: Rhabdomyolysis after strenuous exercise
Fatigue: Often the earliest symptom
Contractures: Develop later than in DMD
Female Carriers
Approximately 10-20% develop cardiomyopathy
Rarely develop significant weakness
May have elevated CK levels
Diagnosis
Serum Creatine Kinase (CK)
Elevation: 5-100 times normal (lower than DMD)
Age-related: Highest in childhood, may normalize later
The study of Becker Muscular Dystrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
[Cardiac and skeletal muscle delivery of biotherapeutics with a blood vessel epicardial substance-targeting peptide.](https://pubmed.ncbi.nlm.nih.gov/41506143/) (2026 Jun) - Biomaterials
[Machine learning for site risk prediction in clinical trials: development, external validation, and operational application in site qualification.](https://pubmed.ncbi.nlm.nih.gov/41741318/) (2026 May) - International journal of medical informatics
[Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study.](https://pubmed.ncbi.nlm.nih.gov/41749413/) (2026 Apr) - Journal of cachexia, sarcopenia and muscle
[Screening for brain-related comorbidities in Duchenne muscular dystrophy: Construction, reliability, and validity of the BIND screener.](https://pubmed.ncbi.nlm.nih.gov/41645051/) (2026 Apr) - Developmental medicine and child neurology
[Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.](https://pubmed.ncbi.nlm.nih.gov/41518520/) (2026 Apr) - Neurology and therapy
References
[Unknown, Cardiac and skeletal muscle delivery of biotherapeutics with a blood vessel epicardial substance-targeting peptide (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41506143/)
[Unknown, Machine learning for site risk prediction in clinical trials: development, external validation, and operational application in site qualification (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41741318/)
[Unknown, Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41749413/)
[Unknown, Screening for brain-related comorbidities in Duchenne muscular dystrophy: Construction, reliability, and validity of the BIND screener (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41645051/)
[Unknown, Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41518520/)